15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Effect of the extracellular component of bone marrow mesenchymal stromal cells from healthy donors on hematologic neoplasms and their angiogenesis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors are a promising source of cell therapy. However, their effectiveness in cancer remains less known. This study is the first to evaluate the quality of BM-MSCs obtained from young and elderly healthy volunteers (KNT cells). The KNT cells had normal karyotypes and were positive for MSC markers (CD90, CD73, CD105). When cultured under appropriate conditions, they showed adipogenic or osteogenic potential. Hence, the anti-neoplastic effects of secretory factors [supernatant or extracellular vesicles (EV)] from KNT cells were verified using several neoplastic cells (three multiple myeloma, three myeloid leukemia, and three lymphoma cell lines). The conditioned medium (CM), but not EV, of KNT cells derived from young healthy donors significantly inhibited myeloma and lymphoma cell proliferation, but enhanced myeloid leukemia proliferation. Anti-angiogenesis effect of CM and EV derived from young KNT against hematologic neoplasia-induced angiogenesis was evident and more prominent in CM than in EV but not evident in elderly KNT-derived EV. These findings indicate that the anti-tumor effect of KNT cells depends on the types of hematologic neoplasia, with elements existing in the supernatant and not in EVs. Therefore, BM-MSC may produce soluble factors that affect cell proliferation of neoplasia, causing cell-to-cell communication. The anti-angiogenesis effect of KNT cells depends on the age of BM-MSC donors.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Mesenchymal progenitor cells in human umbilical cord blood.

          Haemopoiesis is sustained by two main cellular components, the haematopoietic cells (HSCs) and the mesenchymal progenitor cells (MPCs). MPCs are multipotent and are the precursors for marrow stroma, bone, cartilage, muscle and connective tissues. Although the presence of HSCs in umbilical cord blood (UCB) is well known, that of MPCs has been not fully evaluated. In this study, we examined the ability of UCB harvests to generate in culture cells with characteristics of MPCs. Results showed that UCB-derived mononuclear cells, when set in culture, gave rise to adherent cells, which exhibited either an osteoclast- or a mesenchymal-like phenotype. Cells with the osteoclast phenotype were multinucleated, expressed TRAP activity and antigens CD45 and CD51/CD61. In turn, cells with the mesenchymal phenotype displayed a fibroblast-like morphology and expressed several MPC-related antigens (SH2, SH3, SH4, ASMA, MAB 1470, CD13, CD29 and CD49e). Our results suggest that preterm, as compared with term, cord blood is richer in mesenchymal progenitors, similar to haematopoietic progenitors.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma

              Emerging evidence suggests that both human stem cells and mature stromal cells can play an important role in the development and growth of human malignancies. In contrast to these tumor-promoting properties, we observed that in an in vivo model of Kaposi's sarcoma (KS), intravenously (i.v.) injected human mesenchymal stem cells (MSCs) home to sites of tumorigenesis and potently inhibit tumor growth. We further show that human MSCs can inhibit the in vitro activation of the Akt protein kinase within some but not all tumor and primary cell lines. The inhibition of Akt activity requires the MSCs to make direct cell–cell contact and can be inhibited by a neutralizing antibody against E-cadherin. We further demonstrate that in vivo, Akt activation within KS cells is potently down-regulated in areas adjacent to MSC infiltration. Finally, the in vivo tumor-suppressive effects of MSCs correlates with their ability to inhibit target cell Akt activity, and KS tumors engineered to express a constitutively activated Akt construct are no longer sensitive to i.v. MSC administration. These results suggest that in contrast to other stem cells or normal stromal cells, MSCs possess intrinsic antineoplastic properties and that this stem cell population might be of particular utility for treating those human malignancies characterized by dysregulated Akt.
                Bookmark

                Author and article information

                Contributors
                cellspowerlab@gmail.com
                t_umezu@tokyo-med.ac.jp
                s-ima@tokyo-med.ac.jp
                chiaki-k@tokyo-med.ac.jp
                junko@hh.iij4u.or.jp
                ohyashik@rr.iij4u.or.jp
                Journal
                Hum Cell
                Hum. Cell
                Human Cell
                Springer Singapore (Singapore )
                0914-7470
                1749-0774
                12 April 2020
                12 April 2020
                2020
                : 33
                : 3
                : 599-609
                Affiliations
                [1 ]Kintaro Cells Power Corporation, Tokyo, Japan
                [2 ]GRID grid.410793.8, ISNI 0000 0001 0663 3325, Department of Advanced Cellular Therapy, , Tokyo Medical University, ; Tokyo, Japan
                [3 ]GRID grid.410793.8, ISNI 0000 0001 0663 3325, Department of Hematology, , Tokyo Medical University, ; 6-7-1 Nishi-shinjuku, Shinjuku, Tokyo, 160-0023 Japan
                [4 ]GRID grid.410793.8, ISNI 0000 0001 0663 3325, Institute of Medical Science, , Tokyo Medical University, ; Tokyo, Japan
                [5 ]GRID grid.410793.8, ISNI 0000 0001 0663 3325, Present Address: Department of Molecular Pathology, , Tokyo Medical University, ; Tokyo, Japan
                Article
                332
                10.1007/s13577-020-00332-y
                7324432
                32281045
                6d9ab262-745d-41b4-9ff5-6d3c83e91dfc
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 30 September 2019
                : 11 February 2020
                Categories
                Research Article
                Custom metadata
                © Japan Human Cell Society 2020

                Cell biology
                bone marrow stromal cells,donor age,growth inhibitory effect,conditioned medium,angiogenesis

                Comments

                Comment on this article